Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm - $3.6M U.S. Zokinvy® Net Sales in Q1 2021 News provided by Share this article Share this article PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therap...